A skin condition may arguably have a greater impact on the well-being of adolescents than on adults, underlining the importance of Sanofi and Regeneron Pharmaceuticals Inc. reporting on May 16 positive Phase III results with Dupixent (dupilumab) in the younger age group of patients with inadequately controlled moderate-to-severe atopic dermatitis.
The interleukin4/IL-13 inhibitor, Dupixent, is the first and only biologic to show positive results as monotherapy in adolescents aged 12 to 17 years with inadequately controlled disease, the companies say, and a US marketing submission to extend the product's
